These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34985381)

  • 1. Routinely accessible parameters of mineralocorticoid receptor function, depression subtypes and response prediction: a post-hoc analysis from the early medication change trial in major depressive disorder.
    Engelmann J; Murck H; Wagner S; Zillich L; Streit F; Herzog DP; Braus DF; Tadic A; Lieb K; Műller MB
    World J Biol Psychiatry; 2022 Oct; 23(8):631-642. PubMed ID: 34985381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression.
    Murck H; Braunisch MC; Konrad C; Jezova D; Kircher T
    Int Clin Psychopharmacol; 2019 Jan; 34(1):18-26. PubMed ID: 30300165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial.
    Tadić A; Gorbulev S; Dahmen N; Hiemke C; Braus DF; Röschke J; van Calker D; Wachtlin D; Kronfeld K; Gorbauch T; Seibert-Grafe M; Lieb K;
    Trials; 2010 Feb; 11():21. PubMed ID: 20187947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-based biomarker selection - Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression.
    Büttner M; Jezova D; Greene B; Konrad C; Kircher T; Murck H
    J Psychiatr Res; 2015; 66-67():24-37. PubMed ID: 25959615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor-related markers and outcome of major depression: focus on blood pressure and electrolytes.
    Murck H; Ploch M; Montgomery S
    Int Clin Psychopharmacol; 2018 Jul; 33(4):224-228. PubMed ID: 29489494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
    Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K
    BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder.
    Wagner S; Helmreich I; Wollschläger D; Meyer K; Kaaden S; Reiff J; Roll SC; Braus D; Tüscher O; Müller-Dahlhaus F; Tadić A; Lieb K
    PLoS One; 2018; 13(4):e0194574. PubMed ID: 29668746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
    Jain R; Chen D; Edwards J; Mathews M
    Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response.
    Lieb K; Dreimüller N; Wagner S; Schlicht K; Falter T; Neyazi A; Müller-Engling L; Bleich S; Tadić A; Frieling H
    Front Psychiatry; 2018; 9():511. PubMed ID: 30459647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder.
    Tadić A; Wagner S; Gorbulev S; Dahmen N; Hiemke C; Braus DF; Lieb K
    BMC Psychiatry; 2011 Jan; 11():16. PubMed ID: 21269443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
    Eudy RJ; Sahasrabudhe V; Sweeney K; Tugnait M; King-Ahmad A; Near K; Loria P; Banker ME; Piotrowski DW; Boustany-Kari CM
    J Transl Med; 2011 Oct; 9():180. PubMed ID: 22017794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid and mineralocorticoid receptor polymorphisms and recurrence of major depressive disorder.
    Hardeveld F; Spijker J; Peyrot WJ; de Graaf R; Hendriks SM; Nolen WA; Penninx BW; Beekman AT
    Psychoneuroendocrinology; 2015 May; 55():154-63. PubMed ID: 25765757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression.
    Dreimüller N; Schlicht KF; Wagner S; Peetz D; Borysenko L; Hiemke C; Lieb K; Tadić A
    Neuropharmacology; 2012 Jan; 62(1):264-9. PubMed ID: 21803060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of body mass index (BMI) with treatment outcomes in patients with major depressive disorder.
    Xiao L; Zhou J; Galling B; Chen RS; Wang G
    J Affect Disord; 2021 Feb; 281():799-804. PubMed ID: 33243554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.
    Lv X; Si T; Wang G; Wang H; Liu Q; Hu C; Wang J; Su Y; Huang Y; Jiang H; Yu X
    BMC Psychiatry; 2016 Jul; 16():240. PubMed ID: 27422150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.